Drug intelligence / Profile preview

MAK2375

Development stage: Preclinical
Lead developer: MAK Scientific
Modality: Small Molecules

Overview

MAK2375 is a preclinical-stage small molecule being developed by MAK Scientific Management for the treatment of Cannabis Use Disorder. It functions as a dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), the two primary enzymes responsible for the degradation of the endocannabinoids anandamide and 2-arachidonoylglycerol (2-AG). By preventing the breakdown of these endogenous ligands, MAK2375 aims to stabilize endocannabinoid signaling, potentially alleviating withdrawal symptoms and reducing the reinforcing effects of cannabis.

Targets

FAAHMGLL (Monoacylglycerol lipase)

Beyond the preview

Go deeper on MAK2375.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAK2375.

Explore the full profile